Search Results 171-180 of 15179 for TNF

1. Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL - Mayo Clinic

   Being treated with anti-TNF therapies or has been treated with an anti-TNF therapy within 5 half-lives of randomization. Participating Mayo Clinic locations.

2. Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma - Mayo Clinic

   Immunosuppressive mediations (steroids, tumor necrosis factor (TNF)-inhibitors, azathioprine, etc.) within the past 6 weeks; Active or chronic infection with ...

3. A Study to Evaluate the Safety and Effectiveness of BMS-986165 in Subjects with Moderate-to-Severe Ulcerative Colitis (UC) - Mayo Clinic

   ... tumor necrosis factor (TNF)-α agents, integrin inhibitor. Exclusion Criteria: Participant with current diagnosis of Crohn's disease (CD) or diagnosis of ...

4. A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302) - Mayo Clinic

   ... TNF. Subjects receiving any treatment(s) for UC are eligible provided they have been, and are anticipated to be, on a stable dose for the designated period ...

5. Nhan L. Tran, Ph.D. - Mayo Clinic Faculty Profiles

   Tumor necrosis factor receptor superfamily biology in cancer; Identification of novel drug targets, high-throughput screening for drug discovery and ...

6. Curriculum - Summer Undergraduate Research Fellowship (SURF) - Mayo Clinic College of Medicine & Science

   The Sensitizing Effects of TRAF2 Deficiency on TNF- and IFNy-Induced Cancer Cell Death; Utilizing Molecular Dynamics Simulations to Characterize Pathogenic ...

7. Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease - Mayo Clinic

   ... tumor necrosis factor-alpha (TNF-α) antagonist for their underlying CD (does not require treatment failure for currently active draining fistula). France ...

8. A Study to Evaluate Safety and Effectiveness of SHP647 as Induction Therapy in Participants with Moderate-to- Severe Crohn's Disease - Mayo Clinic

   ... TNF. Subjects who have had an inadequate response to sulfasalazine or mesalamine should have also failed at least 1 other conventional treatment such as ...

9. David A. Wetter, M.D. - Mayo Clinic Faculty Profiles

   Paradoxical autoimmune side effects of tumor necrosis factor-alpha inhibitors, including psoriasis, lupus and vasculitis. Significance to patient care. Dr ...

10. A Study to Evaluate TAK-018 for Prevention of the Recurrence of Postoperative Crohn's Disease (CD) - Mayo Clinic

    This includes anti-tumor necrosis factor-alpha (TNF-α) and anti-integrin therapy, anti- interleukin (IL) 12/23, thiopurines and other immunomodulators ...